F-star Presents New Data on OX40/CD137 Tetravalent Bispecific Antibody at the SITC 2019 Annual Meeting
8.11.2019 15:00:00 EET | Business Wire | Press release
F-star Therapeutics (“F-star”), a clinical-stage biopharmaceutical company focused on transforming the lives of patients with cancer through the development of innovative tetravalent bispecific (mAb2™) antibodies, today announces that new preclinical data on FS120, a mAb² product candidate targeting OX40 and CD137, will be presented at the Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting in National Harbor, Maryland, United States, being held from 06 - 10 November 2019.
FS120 is a potentially best-in-class dual agonist that has the potential to overcome cancer resistance by simultaneously engaging OX40 (CD134, TNFRSF4) and CD137 (4-1BB), two receptors found on the surface of tumor-infiltrating lymphocytes. Targeting this class of receptors using bispecific tetravalent binding mobilizes multiple arms of the immune system, which research shows is essential for eliminating tumors. F-star’s preclinical data demonstrated that FS120’s crosslink-dependent approach has the potential to provide therapeutic benefit, for example in combination with checkpoint antagonists, and reverse T cell exhaustion in immunosuppressive tumor environments.
Neil Brewis, CSO of F-star said “Recent clinical trials involving agonist molecules have reported that a meaningful anti-cancer response is often associated with liver toxicity, in line with preclinical observations. F-star’s OX40/CD137 mAb² antibody is showing preclinical evidence that an effective tumor-killing response can be decoupled from liver inflammation. We look forward to progressing FS120 into the clinic as we aim to potentially improve treatment outcomes for patients with difficult-to-treat cancers.”
Some CD137 agonist antibodies have been shown to induce adverse effects either in clinical or in preclinical studies as they constitutively activate T cells and thus release cytotoxic immunity outside of the tumor. In contrast, FS120 is designed to mitigate off-target toxicity through conditional, crosslink-dependent activation upon binding to both OX40 and CD137, which are predominantly present on T cells in the tumor microenvironment.
F-star expects to submit an IND application for FS120 during the fourth quarter of 2019.
Details of the poster are below:
Crosslink-independent CD137 agonism is associated with liver inflammation
Abstract poster number: P775
Poster hall location: Prince George AB
Poster hall hours: 07:00 to 20:00 on Friday 08 November 2019
Poster presentation hours: 12:30 to 14:00 and 18:30 to 20:00 on Friday 08 November 2019
- ENDS -
About F-star
F-star is a clinical-stage immuno-oncology company singularly focused on transforming the lives of patients with cancer through the development of its innovative tetravalent mAb2 bispecific antibodies. With four distinct binding sites in a natural human antibody format, F-star believes its proprietary approach will overcome many of the challenges facing current immuno-oncology therapies. F-star’s vision is to transform the treatment of cancer through the development of differentiated and well-tolerated mAb2 bispecific antibodies, which are designed to simultaneously address multiple immune evasion pathways that limit the effect of current immuno-oncology therapies.
mAb2™ is a trademark of F-star.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191108005210/en/
Contact information
For investor enquiries
Lindsey Trickett
VP Investor Relations & Communications
+1 240 543 7970
lindsey.trickett@f-star.com
Consilium Strategic Communications
Chris Gardner, Sue Stuart, David Daley
Tel: +44 (0)20 3709 5700
E-mail: F-star@consilium-comms.com
For media enquiries
Pierre Peotta
Communications Manager
+44 (0)1223 948 094
+44 (0)7392 080 279
pierre.peotta@f-star.com
US
Catherine London, US President
Tel: +1 917-763-2709
E-mail: F-star@consilium-comms.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Lenovo Brings Production-Scale AI to Hannover Messe 2026, Delivering Up to 85% Faster Lead Times for Manufacturers21.4.2026 10:00:00 EEST | Press release
Manufacturers are under increasing pressure to improve efficiency, resilience, and responsiveness in the face of ongoing supply chain volatility and rising operational complexity. In this environment, AI is no longer a future ambition but an operational necessity. With 94% planning to increase AI investment in 20261 and an expected $2.86 return for every dollar spent2, the priority has shifted from experimentation to execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421992136/en/ ThinkStation PGX and Lenovo ThinkEdge Solution 2 At Hannover Messe 2026, Lenovo in partnership with NVIDIA are demonstrating how manufacturers can close that gap by deploying AI solutions already proven at scale across its own global operations, delivering measurable improvements in lead time, cost, quality, and productivity. “Manufacturers don’t need more AI pilots. They need AI that runs at scale in production,” said Jonathan Wu, Chief
Lenovo Brings Production-Scale AI to Hannover Messe 2026, Delivering Up to 85% Faster Lead Times for Manufacturers21.4.2026 10:00:00 EEST | Press release
Manufacturers are under increasing pressure to improve efficiency, resilience, and responsiveness in the face of ongoing supply chain volatility and rising operational complexity. In this environment, AI is no longer a future ambition but an operational necessity. With 94% planning to increase AI investment in 20261 and an expected $2.86 return for every dollar spent2, the priority has shifted from experimentation to execution. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260421992136/en/ ThinkStation PGX and Lenovo ThinkEdge Solution 2 At Hannover Messe 2026, Lenovo in partnership with NVIDIA are demonstrating how manufacturers can close that gap by deploying AI solutions already proven at scale across its own global operations, delivering measurable improvements in lead time, cost, quality, and productivity. “Manufacturers don’t need more AI pilots. They need AI that runs at scale in production,” said Jonathan Wu, Chief
Bringg Welcomes Chris Conway as Senior Vice President and General Manager, EMEA21.4.2026 08:00:00 EEST | Press release
Bringg, the last-mile performance leader, today announced Chris Conway's appointment as Senior Vice President and General Manager, EMEA. Conway will lead Bringg's commercial strategy, customer relationships, and go-to-market operations across the region. Conway brings more than 20 years of experience in eCommerce, digital commerce, and operational transformation at three of the UK's largest grocery retailers. Most recently, he served as Managing Director of Quick Commerce and Food Operating Board Member at Co-op, where he built and scaled a £500 million-plus q-commerce operation delivering from nearly 2,000 stores. He also founded Peckish, a rapid delivery app that gave independent retailers access to q-commerce technology. He also led Asda's online grocery business to more than £1 billion in revenue and 20% market share, and ran the online commercial team at Morrisons. Conway holds an AI certificate from Oxford Saïd Business School. “Chris built one of the UK's most successful deliver
Barnes Molding Solutions Becomes SPECTRIX21.4.2026 08:00:00 EEST | Press release
Barnes Molding Solutions is now SPECTRIX. The new Brand offers the full Spectrum of injection molding capabilities delivered by its leading brands - Männer, Foboha, Synventive, Priamus, Thermoplay, and Gammaflux. The change, announced at Chinaplas 2026, reflects the integration of core technologies within a single organization: part design, material science, hot runner and mold technology, sensors & controls and injection molding. Day-to-day operations remain unchanged, including contacts, contracts, and processes. Focused on global growth Under President Marcello Vendemiati, SPECTRIX is strengthening its global market focus and expanding its footprint. This strategy is already visible with the opening of a new manufacturing facility in Pune, India. Another production site near Detroit, USA, is set to open soon. The name SPECTRIX combines “spectrum” and “plastics,” while reflecting the company’s core strengths: expertise, experience, and excellence. Its tagline, “Enduring Advantage, En
Barnes Molding Solutions Becomes SPECTRIX21.4.2026 08:00:00 EEST | Press release
Barnes Molding Solutions is now SPECTRIX. The new Brand offers the full Spectrum of injection molding capabilities delivered by its leading brands - Männer, Foboha, Synventive, Priamus, Thermoplay, and Gammaflux. The change, announced at Chinaplas 2026, reflects the integration of core technologies within a single organization: part design, material science, hot runner and mold technology, sensors & controls and injection molding. Day-to-day operations remain unchanged, including contacts, contracts, and processes. Focused on global growth Under President Marcello Vendemiati, SPECTRIX is strengthening its global market focus and expanding its footprint. This strategy is already visible with the opening of a new manufacturing facility in Pune, India. Another production site near Detroit, USA, is set to open soon. The name SPECTRIX combines “spectrum” and “plastics,” while reflecting the company’s core strengths: expertise, experience, and excellence. Its tagline, “Enduring Advantage, En
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom